Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent

Author(s): Rakesh Ravindra Somani* and Pratip Kashinath Chaskar

Volume 18, Issue 4, 2018

Page: [363 - 368] Pages: 6

DOI: 10.2174/1389557516666160817102701

Price: $65

Abstract

Some melanomas and hepatocellular carcinomas have been shown to be auxotrophic for arginine. Arginine deiminase (ADI), an arginine degrading enzyme isolated from Mycoplasma, can inhibit the growth of these tumors. It is a catabolizing enzyme which catabolizes arginine to Citrulline. Tumor cells do not express an enzyme called arginosuccinate synthetase (ASS) and hence, these cells become auxotrophic for arginine. It is found that ADI is specific for arginine and did not degrade other amino acid. This review covers various aspects of ADIs like origin, properties and chemical modifications for better antitumor activity.

Keywords: Arginine, Arginine deiminase (ADI), Arginosuccinate synthetase (ASS), Arginosuccinate lyase (ASL), Hepatocellular carcinoma, malignant melanoma.

« Previous Next »
Graphical Abstract


Rights & Permissions Print Cite
Article Metrics
48
3
© 2025 Bentham Science Publishers | Privacy Policy